Unbiased headlines. Facts, not spin.
Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.
Two RAS-Blocking Pills Shrink Pancreatic Tumors in Early Trials Presented in Barcelona

Two drugs aimed at the RAS gene mutation, long considered impossible to target, posted new pancreatic cancer data Friday, Nov. 20, at the EORTC-NCI-AACR Symposium in Barcelona. Neither result is a cure. Both are early. For a disease with few options, the numbers are still hard to ignore.
Daraxonrasib plus chemo in first-line disease
Revolution Medicines presented a Phase 1/2 trial pairing its daily pill daraxonrasib, sold as Rasonque, with standard chemotherapy: gemcitabine and nab-paclitaxel. The trial enrolled 61 patients whose pancreatic cancer had already spread and who had not yet been treated for advanced disease.
Tumors shrank in 60.7% of patients, and in 8.2% they disappeared entirely on scans. The combination stopped tumor growth in 90.2%. Median follow-up was 18 months.
Median progression-free survival was 12.8 months, and 76.6% of patients were alive at one year. Dr. Wungki Park, the lead investigator and a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center, said the team was seeing "substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year."
The comparison point is grim. In major trials of chemotherapy alone for metastatic pancreatic cancer, tumors shrink in roughly 23% to 42% of patients, growth typically resumes after five to six months, and most patients live 8 to 11 months. National Cancer Institute data put five-year survival for distant-stage disease at about 3%.
Side effects included rash, diarrhea, fatigue and low blood cell counts. They were manageable with standard care, and only 5% of patients stopped treatment because of daraxonrasib. This is a mid-stage, single-arm study with 61 people. It is not a head-to-head randomized trial, and median overall survival has not been reported.
The FDA approved Rasonque on Aug. 26 for metastatic pancreatic cancer after prior treatment. The frontline combination is still investigational.
Erasca's ERAS-0015 enters the race
Erasca, a Nasdaq-listed company based in San Diego, presented Phase 1 data from its AURORAS-1 trial of ERAS-0015, a "pan-RAS molecular glue." The trial began in June 2025 and is still enrolling. As of the presentation it had treated 148 patients, including 83 with pancreatic cancer and 37 with non-small cell lung cancer. Doses ranged from 2 mg to 40 mg, and no maximum tolerated dose has been reached.
At 32 mg, tumors shrank in 11 of 25 previously treated pancreatic cancer patients, or 44%, confirmed by a repeat scan. Erasca said the response rate was 69% in patients with KRAS G12D or G12V mutations. In lung cancer, 3 of 5 patients at 32 mg responded, which Erasca reports as 60%. Those sample sizes are tiny.
Median follow-up was just over four months. No one knows yet how long the responses last, and there are no survival data.
Dr. Judy Wang of Florida Cancer Specialists and Research Institute presented the results. She said ERAS-0015 showed "clinically meaningful activity" in patients with "few if any therapeutic options" and was "well tolerated with few severe side effects." Symposium chair Prof. Elena Garralda, who was not involved, called the activity "encouraging" and said larger Phase 2 and Phase 3 trials are needed.
Among 122 pancreatic patients dosed at 16 to 32 mg, rash, diarrhea, nausea and mouth inflammation were the most common side effects, each affecting at least 10%. Severe treatment-related events, grade 3 or higher, hit 12 patients, or 9.8%. Tech Times reported that the dataset also includes one treatment-related death from lung inflammation (pneumonitis), which the symposium's press release does not mention.
The fight over differentiation
Erasca CEO Jonathan Lim says ERAS-0015 binds the helper protein CypA with 8 to 21 times higher affinity than daraxonrasib and works at about 32 mg, versus roughly 300 mg for the Revolution drug. He also says it causes fewer dose interruptions. Those are the company's claims. The two drugs have not been tested against each other.
Analysts split on whether the data matter. RBC Capital Markets analyst Leonid Timashev, who covers Revolution, wrote that ERAS-0015 "could be a formidable competitor" and that it "continues to demonstrate a better profile on both efficacy and safety in what was a challenging population." Leerink Research analyst Asthika Goonewardene wrote that a lower side effect rate, if confirmed, could open niches Rasonque cannot reach because of its overlapping toxicities with other medicines.
TD Cowen analyst Tyler Van Buren disagreed. He wrote that Erasca's data "fail to meaningfully differentiate from Rasonque, especially considering the multi-year commercial head start Rasonque has on nearest competitors." He added that it is unclear the early results would translate to a superior profile in a larger trial, and that oncologists are getting better at managing Rasonque's side effects.
The response rates Revolution has reported for Rasonque in previously treated patients were 32% overall, and 24% and 50% in G12D and G12V mutations. Erasca's rates look higher on paper. Cross-trial comparisons are error-prone, and Erasca itself says its comparisons are "subject to the limitations of cross-study comparisons."
The companies are also in a legal dispute. Revolution has alleged that ERAS-0015 infringes its patent. Erasca says the claims are without merit.
What comes next
The stakes are high. The American Cancer Society expects about 67,530 Americans to be diagnosed with pancreatic cancer in 2026. More than 90% of pancreatic cancers carry a RAS-family mutation, and more than half of patients are diagnosed after the disease has spread.
Erasca says it plans a Phase 3 trial in first-line pancreatic cancer in the first half of 2027, accelerated from its earlier plan. It also plans a potentially registration-enabling lung cancer trial in the first half of 2027 and a first-line lung Phase 3 between the second half of 2027 and the first half of 2028. Whether a 25-patient cohort and four months of follow-up can carry a drug into that kind of trial, and past an established rival, will be settled by those studies and by the patent case.
Sources used for this briefing
8 links from 8 independent newsrooms (syndicated copies of the same report count once)
These are the sources it draws on, linked so you can verify.